Is Lupus Hereditary? What a 23andMe Polygenic Risk Result Really Means

Is Lupus Hereditary? What a 23andMe Polygenic Risk Result Really Means

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A 2026 multi-ancestry genetic study found 101 risk regions linked to systemic lupus erythematosus (SLE), often just called lupus. It estimated that genetics explains roughly a quarter of who gets the disease. A 23andMe “higher likelihood” polygenic report is a shift in the odds for a group of people, not a diagnosis for one person. Only a rheumatologist’s blood work, urine testing, and clinical exam can confirm lupus.

What you’ll learn

• Why lupus risk comes from many genes working together, not one mutation.
• How to turn abstract genetic risk numbers into a useful picture of personal odds.
• The real difference between a direct-to-consumer (DTC) “likelihood” result — the kind sold by services like 23andMe — and a clinical rheumatology diagnosis.
• What the newest FDA- and Health Canada-approved lupus nephritis treatment involves, and what GINA does and does not protect.

How Lupus Risk Is Inherited: A Polygenic Condition Rooted in the HLA Region

Lupus does not follow a single-gene inheritance pattern. It is not dominant, recessive, or X-linked — meaning carried on the X chromosome — the way some other family conditions are. Instead, risk builds up gradually from common gene variation spread across the whole genome. Researchers call this a polygenic condition. Many genes each add a small piece to overall risk.

A 2026 multi-ancestry study compared 22,494 people with lupus against 1,568,102 people without it. The study found 101 risk regions, called loci. Twelve of those loci had never been found before. Out of 2,209 candidate genes, researchers narrowed the list to 265 as the most likely, using eight separate biological tests.

The single strongest signal sat in a stretch of chromosome 6 called the HLA class II region. This region normally helps the immune system tell the body’s own cells apart from invaders. Within it, a gene named BLK ranked as the top candidate for driving lupus risk.

Researchers separate a “candidate” gene from a proven “causal” gene. A candidate sits near a risk signal and looks likely to matter. A causal gene has stronger evidence that it actually drives disease risk, not just sits near a marker. BLK’s ranking as top candidate reflects the strongest evidence available today, though this research keeps evolving.

The 2026 study also pointed to a signaling pathway called JAK-STAT, which helps immune cells send messages to each other. It also found unusual activity in T cells and B cells, two types of immune cells that end up attacking the body’s own tissue in lupus.

This genetic map did not appear overnight. A 2015 study mapped 43 lupus risk loci, ten of them new at the time. That work confirmed the HLA class II region as one of the strongest, most consistent genetic signals in lupus. It also linked lupus to overactive type I interferon activity, an immune chemical-messenger response that revs up inflammation.

A 2017 follow-up study fine-mapped the same region across three ancestry groups: European, African American, and Asian. It confirmed HLA class II as the strongest signal in each group studied. The 2026 study builds on this earlier work, using much larger sample sizes to sharpen the picture.

The 2026 study found one more thing worth knowing: a shared genetic link between lupus and three other diseases — rheumatoid arthritis, schizophrenia, and hypertension. Some of the same gene changes nudge risk upward for more than one condition at once. The study also flagged riboflavin, a common B vitamin, as an early drug-repurposing lead. This is not a treatment recommendation of any kind. It is a signal worth studying further in future trials.

Government researchers describe lupus as a disease shaped jointly by genetics, hormones, and a person’s surroundings. None of these three works alone. Picture lupus risk less like a single light switch and more like a dimmer dial with dozens of small hands nudging it at once. No single hand decides the final brightness.

This polygenic pattern is very different from single-gene diseases many readers already know. BRCA1 and BRCA2, linked to breast and ovarian cancer, each involve one gene with a large effect. Cystic fibrosis works the same way, tied to a single gene called CFTR. Lupus has no equivalent single gene. Dozens of common gene changes each add a small nudge, and the HLA class II region simply nudges hardest.

A rheumatologist is the right specialist to evaluate active symptoms. A board-certified genetic counselor can help translate this complex genetic picture into what it means for one family.

Section recap: Lupus risk comes from dozens of common gene changes acting together, led by the HLA class II region and the BLK gene, not from one dominant mutation.

Risk Magnitude: From 25.49% Heritability to Your Real-World Odds

The 2026 study put lupus’s heritability — the share of risk explained by genes — at 25.49% on what researchers call the liability scale. In plain terms, genetics explains about a quarter of why some people get lupus. The other three-quarters comes from hormones, surroundings, and plain chance. That is a real genetic contribution. It is also far from a sure thing.

Compare this to Huntington’s disease, where one gene change almost guarantees illness. Lupus works nothing like that. A quarter of the picture leaves a lot of room for other forces to decide the outcome.

The CDC (Centers for Disease Control and Prevention) estimates that more than 200,000 people live with SLE, the most common form of lupus, in the United States. About 9 in 10 diagnosed adults are women. Lupus is also more common and more severe among Black, Hispanic, Asian American, Pacific Islander, and Native American women than among white women. This gap is wider still for lupus nephritis, a serious kidney complication.

A CDC-funded registry in Georgia offers sharper numbers. It found roughly 5.6 new cases per 100,000 people each year. Overall, about 128 out of each 100,000 people had lupus. The same registry found lupus was much more common among Black women than white women. Black patients were also diagnosed younger and got kidney problems more often.

Doctors mostly treat a close family history of lupus as a reason for extra attention. A parent, sibling, or child with lupus points to a shared genetic and lifestyle background. But most relatives of someone with lupus never get it themselves. Lupus’s spread-out genetic pattern also makes it hard to put an exact number on any one relative’s added risk. A “higher likelihood” flag on a 23andMe report reflects shifted odds for a whole group of people, not a personal guarantee. Most single risk changes each carry only a small effect on their own.

Here is a way to picture it. Imagine 100 people who share a similar genetic profile to a “higher likelihood” flag. Most of them will go through life without ever getting lupus. The label describes shifted odds across a group. It does not forecast the outcome for any one person in that group.

Hormones and surroundings explain why two people with a similar genetic profile can end up very differently. Estrogen is one likely factor, which fits with lupus affecting far more women than men. UV light, certain infections, and some medicines round out the known triggers. None of these works apart from the genetic background described above.

A primary care doctor can help place a family history and a DTC result into proper context.

Section recap: Genetics explains about a quarter of lupus risk. The rest comes from hormones, surroundings, and chance, so a raised risk score is a shift in the odds, not a prediction.

Testing Options in the US and Canada: DTC Polygenic Scores vs. the Real Diagnostic Workup

A 23andMe Health Predisposition “Lupus” polygenic report estimates a group-level chance based on gene changes. It is not a diagnostic test. A genetic counselor can help interpret it, but it cannot replace lab work or a doctor’s exam.

The real diagnostic path looks different. Physicians typically start with an antinuclear antibody test, known as ANA, as an entry screen. A positive ANA on its own is common in the general population. A positive ANA alone does not mean lupus.

If ANA comes back positive, doctors add more tests: anti-double-stranded DNA and complement levels, called C3 and C4, a family of immune proteins. They also order a complete blood count and a urine test to screen for kidney involvement. Doctors may also test for anti-Smith antibodies, another marker used in formal lupus scoring.

Rheumatologists weigh these results together using the 2019 European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) classification checklist. This formal scoring system is used in both research and everyday care. It needs an ANA titer of at least 1:80 as a mandatory starting point. From there, it adds weighted points across seven clinical categories and three lab-based categories. A total score of 10 or more, plus the entry test, classifies a case as lupus.

Here is how the two paths compare:

	DTC polygenic report (e.g., 23andMe)	Clinical diagnostic workup
What it measures	A chance estimate from common gene changes	Actual disease activity, from blood and urine tests
Confirms a diagnosis?	No	Yes, combined with a doctor’s exam
Who orders it	Anyone, no prescription needed	A doctor or rheumatologist
Typical cost path	Usually paid out of pocket	Usually billed through an employer plan (US) or a provincial plan (Canada)
Best next step	Share results with a doctor for context	Confirms or rules out active lupus

A 23andMe report typically shows results as a percentile compared with other people, not as a fixed percent chance of disease. A result in a higher percentile suggests a stronger genetic tendency relative to others, not an imminent diagnosis. Consumer genetic services mostly describe these reports as educational, not as tools for making health choices.

Here is an everyday comparison. Think of the DTC score like a weather forecast showing a raised chance of rain next month. That forecast is useful context. It cannot tell anyone whether to carry an umbrella tomorrow. Only today’s actual sky can answer that question.

A genetic counselor can help interpret a DTC result alongside personal and family history. The National Society of Genetic Counselors keeps a searchable directory at NSGC.org.

Section recap: A 23andMe polygenic score is a starting point, not a diagnostic test. Only blood and urine work interpreted by a rheumatologist can confirm or rule out lupus.

Interpreting Your Result: Polygenic Likelihood vs. Clinical Diagnosis vs. a False Alarm

Three scenarios get confused constantly, and separating them matters:

• A polygenic risk-score probability — a genetic chance estimate from a service like 23andMe, not based on current symptoms.
• A confirmed clinical diagnosis — meeting the EULAR/ACR scoring checklist after blood work, urine tests, and a doctor’s exam.
• An incidental positive ANA — a single lab marker common in healthy people that does not by itself mean lupus.

Current polygenic scores explain only part of total lupus heritability. They cannot predict which organs will be affected. Skin, joints, kidneys, or the brain and nervous system can each be involved to different degrees. That organ-specific detail matters far more, clinically, than the score itself.

An elevated 23andMe result does not confirm active disease today. A reassuring, lower-risk result also does not rule out getting lupus later. A person’s surroundings interact with genetic tendency over time. UV exposure, certain infections, and some medicines can all play a role.

Picture a smoke detector with an adjustable sensitivity dial. A DTC score can turn that dial up or down. It does not mean smoke is present right now. A low setting also does not mean a fire could never start later.

A raised risk score does not equal certainty, and a low score does not equal permanent safety. Both extremes can cause real stress. Bringing a result to a primary care visit, instead of researching it alone late at night, tends to ease that stress and clarify next steps.

New symptoms deserve prompt attention no matter what a genetic result shows. A butterfly-shaped facial rash is one warning sign. New joint swelling is another, and protein showing up in a urine test is a third. Any of these should prompt a visit to a primary care doctor or rheumatologist. Waiting on a DNA report first is not the right move.

Section recap: A DTC risk score, a confirmed diagnosis, and an incidental positive ANA are three different things. New symptoms always call for a clinical check, no matter what any genetic result shows.

Prevention and Early Detection: Realistic Surveillance, Not a Guarantee

Right now, there is no way to change the root genetic tendency toward lupus. Prevention here means useful early detection, not removing risk.

Sun protection is the most evidence-backed everyday step available. Lupus is well known to be photosensitive, meaning sensitive to sunlight. UV exposure can trigger flares in people who already carry genetic risk. Broad-spectrum sunscreen helps. Protective clothing helps too, and so does avoiding strong sun during peak hours. This routine overlaps with standard sun safety for skin cancer prevention.

Quitting smoking is another concrete step many doctors recommend for people managing an autoimmune disease. This is general health advice, not a claim tied to lupus-specific research.

Watch for these early warning signs, especially with a family history of lupus:

• Joint pain or swelling that does not go away
• A facial rash that follows sun exposure, especially across the cheeks and nose
• Unexplained tiredness that does not improve with rest
• Mouth ulcers with no clear cause
• Sunburn or rash after only brief sun exposure

None of these signs alone confirms lupus. Any of them is worth a talk with a doctor.

For a first-degree relative of someone with lupus, screening choices belong to a doctor. Whether periodic ANA or urine testing makes sense is a health judgment call, not a self-directed plan. No drug exists yet that prevents lupus before symptoms start.

Section recap: Sun protection, quitting smoking, and prompt attention to early symptoms are the useful prevention steps. No treatment yet prevents the root genetic tendency itself.

Current Treatment Landscape: The Newest FDA- and Health Canada-Approved Option

Common lupus medicines include hydroxychloroquine, an anti-malaria drug also used for skin and joint symptoms, and NSAIDs, over-the-counter pain relievers. Short courses of steroid medicines, also called corticosteroids, calm inflammation quickly. For more severe organ involvement, such as active kidney disease, treatment moves to stronger medicines that calm the immune system.

For decades, standard lupus nephritis treatment relied on two older drugs: mycophenolate mofetil and cyclophosphamide, both paired with steroid medicines. A 2018 Cochrane review compared these regimens directly. It found broadly similar results for bringing on remission, but different side effects between the two. It also found that a large share of patients never reached a complete renal response, meaning the kidneys returned to near-normal function on lab tests, on standard treatment alone. That treatment gap is exactly what newer add-on drugs have tried to close.

The table below shows how the three lupus-nephritis-specific drug approvals stack up:

Drug	Type	Approval / authorization
Belimumab (Benlysta)	Antibody add-on treatment	FDA, 2020
Voclosporin (Lupkynis)	Oral add-on treatment	FDA, 2021
Obinutuzumab (Gazyva)	Antibody add-on treatment targeting CD20, a protein on certain immune cells	FDA, 2025-10-17; Health Canada, 2026-01-22

The belimumab and voclosporin dates and the Gazyva approvals are drawn from FDA and Health Canada regulatory records.

The newest evidence comes from the phase 3 REGENCY trial. It was double-blind and placebo-controlled, run across 15 countries on four continents. At 76 weeks, 46.4% of patients on Gazyva plus standard treatment reached a complete renal response, versus 33.1% on standard treatment alone. Standard treatment in the trial meant mycophenolate mofetil combined with steroid medicines. Results appeared in the New England Journal of Medicine on February 7, 2025.

Regulators moved on this evidence quickly. The FDA approved Gazyva as an add-on treatment for adults with active lupus nephritis on October 17, 2025. That made it only the third drug ever specifically approved for lupus nephritis in the United States. Health Canada authorized the same use on January 22, 2026. Its decision cited both the earlier phase 2 NOBILITY trial and the phase 3 REGENCY results.

No approved drug cures lupus, and none reverses the root genetic tendency found by genome studies. Current approvals target disease activity and certain organ damage, mainly in the kidneys. They do not touch the root genetic cause.

Insurance access to newer biologic therapies like Gazyva often needs prior sign-off from a health plan. Coverage details vary by insurer in the US and by province in Canada. A rheumatology office’s billing staff can usually help with this process.

Regular kidney function tests, blood counts, and infection checks are standard parts of care on any of these medicines. None of the drugs discussed here are risk-free. A rheumatologist weighs those risks against the expected benefit for each patient.

Whether an add-on biologic like Gazyva fits your case needs a personal discussion. A rheumatologist familiar with a patient’s full history is best placed to make that call.

Section recap: Gazyva’s FDA approval in October 2025 and Health Canada authorization in January 2026 mark the third lupus-nephritis-specific drug approval in US/Canada history, after belimumab and voclosporin.

Family Implications: What Your Result Means for Children, Siblings, and Parents

Lupus risk is spread across many genes rather than concentrated in one. Because of this, there is no clean, step-by-step process for testing relatives the way there is for a single-gene disease like BRCA1 or BRCA2. That process, used for single-gene diseases, is called cascade testing: relatives are offered the same genetic test once one family member tests positive.

Close relatives of someone with lupus carry a somewhat higher chance of getting lupus themselves, though most never do. The 2026 study’s shared-genetics finding adds a useful nuance here: lupus shares genetic ground with rheumatoid arthritis and other diseases. This suggests something important for families. Shared genetics may surface as a different autoimmune disease entirely, not necessarily lupus itself.

Genetics explains only part of lupus risk, about a quarter, per the 2026 heritability estimate. That is why even identical twins, who share nearly all of their DNA, do not both get lupus each time one of them does. That gap between shared genes and shared outcome shows how much environment and chance still matter, even within a single family.

Ancestry also shapes this picture in a known way. Fine-mapping research found a higher cumulative genetic risk load in people of African and Asian ancestry. This partly explains why the disease tends to run more severe in these groups.

Practical family guidance centers on awareness, not genetic screening. A relative with unexplained joint pain should mention the family history to a doctor, as should a relative with a lasting rash or ongoing tiredness. Using a DTC polygenic test purely as a screening tool is mostly not useful here. Neither a high score nor a low score is actionable on its own without matching symptoms.

This situation looks more like a family history of heart disease than a single-gene cancer syndrome. It raises general awareness. It justifies mentioning the history to a doctor. It does not automatically trigger a targeted test for each relative in the family.

A genetic counselor can help a family sort through which relatives, if any, might benefit from further evaluation. This kind of family mapping works best as an ongoing conversation, not a one-time decision.

Section recap: Lupus has no clean cascade-testing pathway for relatives; family guidance means raising symptom awareness with a doctor, not pursuing predictive genetic screening.

Psychosocial Impact: GINA Protections, Insurance Gaps, and Disparities in Care

The US Genetic Information Nondiscrimination Act, known as GINA, became federal law in 2008. It stops health insurers from using a genetic test result against someone, including a 23andMe polygenic score. Insurers cannot use it to deny coverage, set premiums, or decide eligibility. GINA also stops employers from using genetic information in hiring, firing, or promotion decisions.

Here is what GINA does and does not cover:

Covered by GINA	Not covered by GINA
Health insurance eligibility and premiums	Life insurance
Employer hiring, firing, and promotion decisions	Disability insurance
—	Long-term-care insurance

Anyone considering DTC genetic testing should know this gap first, before applying for one of those uncovered policy types.

Living with lupus carries emotional weight apart from any genetic result. The disease often comes and goes in flares, followed by calmer stretches, and its tiredness is often invisible to coworkers, friends, and even family. Deciding when and how to tell relatives about a genetic-risk result adds another layer of difficulty, mainly before any symptoms appear.

The gap in lupus nephritis severity is well known. Women of African, Asian, Hispanic, and Native American ancestry face higher rates and greater severity. This remains an active area of genetics and health-equity research. No single article can resolve it, but naming it plainly matters more than the vague mentions common across most lupus content online.

Patient-advocacy groups offer support beyond what any article can provide. The Lupus Foundation of America estimates that at least 1.5 million Americans live with some form of lupus. It also estimates that roughly 1 in 3 people with lupus get lupus nephritis, with higher rates among Black, Hispanic, and Asian American patients.

Workplace accommodations can help with the unpredictable tiredness and joint pain that often come with active lupus. Many employers offer flexible scheduling or remote work once a diagnosis is on file. Support groups connect patients with others managing the same up-and-down course.

Family disclosure choices deserve careful thought rather than a rushed announcement. Some people choose to share a DTC result with close relatives right away, hoping it prompts earlier awareness of symptoms. Others prefer to wait for symptoms or a confirmed diagnosis before raising the topic. Neither approach is wrong. A genetic counselor can help a family think through timing, mainly when a teenager or young adult relative is involved.

Section recap: GINA blocks genetic discrimination in US health insurance and employment but not in life, disability, or long-term-care insurance. Disparities in lupus nephritis severity remain an active research focus.

Frequently Asked Questions

Will I get the disease if my 23andMe result shows a higher likelihood for lupus? No, not automatically. A higher-chance result is a shift in the odds for a group of people, not a personal guarantee. Most people with a similar genetic profile never get lupus. Only a rheumatologist’s exam and blood work can confirm or rule out active disease.

Will my children inherit lupus from me? Lupus does not follow a single-gene inheritance pattern, so there is no fixed percentage to hand down the way there is with some other diseases. Children of someone with lupus carry a somewhat higher chance. That is not a guarantee, and most children never get the disease.

Can a genetic lupus risk result affect my health or life insurance? GINA stops US health insurers and employers from using a genetic test result against someone. It does not cover life insurance, disability insurance, or long-term-care insurance. Those policy types remain a real gap to understand before testing or sharing results.

Can my employer find out about my genetic test result? Under GINA, employers cannot legally use genetic information in hiring, firing, or promotion decisions.

Should I get a second opinion after an unexpected result? Yes, whenever symptoms or family history raise real questions. A board-certified genetic counselor can add clarity. So can a second rheumatologist, since lupus is such a variable disease. A second opinion is reasonable any time a result changes how someone feels about their own health.

Summary

Lupus is a polygenic autoimmune disease, not a single-gene disorder. The 2026 multi-ancestry study identified 101 risk regions and named BLK as the leading candidate gene within the HLA class II region. It also estimated that genetics explains about a quarter of who gets lupus. A 23andMe “higher likelihood” result reflects that partial genetic picture. It is not a diagnosis, and it cannot replace ANA-based blood work interpreted by a rheumatologist.

Treatment has moved forward in a real way. Gazyva’s FDA approval in October 2025 added a third targeted option for lupus nephritis, and Health Canada’s authorization followed in January 2026. Both decisions rested on REGENCY trial data showing a higher complete renal response rate than standard treatment alone. GINA protects against genetic discrimination in US health insurance and employment. Real gaps still remain for life, disability, and long-term-care coverage.

Anyone with a family history of lupus should raise these questions directly with a doctor. The same goes for anyone with a new DTC risk flag. Unexplained symptoms such as joint pain, a sun-triggered rash, or ongoing tiredness deserve the same talk.

A useful starting point is simple: write down the result, any symptoms noticed, and relevant family history before the appointment. Bring that summary to a primary care doctor, a rheumatologist, or a genetic counselor. A focused talk, grounded in real evidence rather than searching alone online, tends to produce the clearest next steps.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Multi-ancestry genome-wide association meta-analysis of systemic lupus erythematosus. Mammalian Genome, 2026;37(1):95. PMID 42581184. DOI 10.1007/s00335-026-10266-9. https://pubmed.ncbi.nlm.nih.gov/42581184/
2. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis: The Phase 3 REGENCY Trial. New England Journal of Medicine, 2025-02-07;392(15):1471-1483. DOI 10.1056/NEJMoa2410965. https://doi.org/10.1056/NEJMoa2410965
3. US FDA, openFDA Drugs@FDA Database — Obinutuzumab (Gazyva), BLA 125486, Lupus Nephritis Indication. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486
4. Health Canada, Notice of Compliance Database — Obinutuzumab (Gazyva), Lupus Nephritis Indication. https://health-products.canada.ca/noc-ac/index-eng.jsp
5. Centers for Disease Control and Prevention — Lupus: Data, Statistics, and Risk Factors. https://www.cdc.gov/lupus/
6. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH — Systemic Lupus Erythematosus (Lupus). https://www.niams.nih.gov/health-topics/lupus
7. US Congress — Genetic Information Nondiscrimination Act of 2008, Pub. L. 110-233. https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008
8. Bentham J, Morris DL, Cunninghame Graham DS, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in lupus. Nature Genetics, 2015. https://pubmed.ncbi.nlm.nih.gov/26502338/
9. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017. https://pubmed.ncbi.nlm.nih.gov/28860548/
10. Lim SS, Bayakly AR, Helmick CG, et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry. Arthritis & Rheumatology, 2014. https://pubmed.ncbi.nlm.nih.gov/24504809/
11. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology, 2019. https://pubmed.ncbi.nlm.nih.gov/31385462/
12. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database of Systematic Reviews, 2018. https://pubmed.ncbi.nlm.nih.gov/30035305/
13. National Society of Genetic Counselors (NSGC) — Find a Genetic Counselor Directory. https://www.nsgc.org/findageneticcounselor
14. Lupus Foundation of America — Lupus Facts and Statistics; Lupus Nephritis: Treatment and Outlook. https://www.lupus.org/resources/lupus-nephritis

Last updated: 2026-09-19

Author: genelumen editorial team. This article aggregates 14 sources from peer-reviewed research and public health agencies (tier 1=10, tier 2=3, tier 3=1), including NIH, CDC, Health Canada, and FDA data.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

🌐 日本語版 (Japanese version): https://genelumen.com/ja/ja-genetic-diseases/lupus-sle-polygenic-risk